Oncology
New personalized cancer vaccine in the making thanks to unique Belgian collaboration
The young Belgian start-up Persomed is unique – it was founded in 2020 by four partners each with relevant expertise […] November 23, 2022 · BioVox
V-Bio Ventures leads Sibylla Biotech's EUR 23 million Series A to advance a novel therapeutic approach for undruggable diseases
Ghent, Belgium, 4 October 2022 – V-Bio Ventures announces the successful close of a EUR 23 million Series A financing […] October 4, 2022 · V-Bio Ventures
Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease
Augustine Therapeutics is a VIB and KU Leuven spin-off developing innovative therapies for peripheral and central nervous system disorders. The […] August 17, 2022 · V-Bio VenturesAugustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board, and broadens therapeutic indications
Leuven, Belgium, 10 May 2022 – Augustine Therapeutics, a biotech company developing novel therapies for neuromuscular and neurodegenerative disorders, appoints […] May 10, 2022 · Turnstone Communications
IBA and SCK CEN partnership to produce rare radioisotope for cancer treatments
The radioisotope Actinium-225 shows clear promise in the battle against cancer, but to fulfil its potential we will need to […] April 20, 2022 · BioVox
Drug development trends: from common to orphan indications… and back again?
Over the past few decades, pharma has gradually shifted its target patient focus for newly launched drugs from large to […] April 20, 2022 · V-Bio Ventures
Abscint labels antibodies with radioactive material to spot harmful cells
Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies […] March 16, 2022 · BioVoxV-Bio Ventures’ Portfolio Company Precirix raises EUR 80 million in Series B to advance its pipeline of precision radiopharmaceuticals
Ghent, Belgium, 16 March 2022 – V-Bio Ventures today announced the completion of a EUR 80 million Series B round […] March 16, 2022 · V-Bio VenturesElmediX raises nearly 12 million euros to develop innovative heat technology to fight cancer
Mechelen, Belgium, January 25, 2022 – Belgian company ElmediX is developing intensive and controlled heat treatments for the treatment of […] January 25, 2022 · Turnstone CommunicationsNew start-up Trince raises EUR 4 million for innovative technology to produce personalized cancer therapies safer, cheaper, and faster
Ghent, Belgium, 6 December 2021 – Trince, a spin-off of Ghent University (UGent), is developing innovative and efficient technology to insert […] December 6, 2021 · Turnstone Communications
The dark matter of the genome: Flamingo Therapeutics taps potential of mysterious RNA for cancer therapies
Things are moving fast for Flamingo Therapeutics, a Leuven-based biotech company developing innovative RNA-targeted cancer therapies. The start-up is a […] October 20, 2021 · BioVoxEsoBiotec ready to transform cell therapy cancer treatments
– EsoBiotec, a recently founded biotech company, announces a EUR 6 million pre-series A round comprised of non-dilutive funding from […] September 30, 2021 · Turnstone CommunicationsNewton Biocapital invests in PRISM BioLab to support development of a unique peptide mimetic technology platform to discover new drugs for intractable diseases
Brussels, Belgium / Tokyo, Japan – 9 September 2021 – Newton Biocapital (“Newton”), a life sciences investment fund active in […] September 9, 2021 · Turnstone Communications